Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christelle Bouygues

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|July 16, 2019
A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and WhyMwango Kashoki, Zahra Hanaizi, Stella Yordanova, et al.
Clinical Pharmacology and Therapeutics|May 3, 2023
Biomarker-Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European UnionCiska Verbaanderd, Ana Trullás Jimeno, Jörg Engelbergs, et al.
Frontiers in Medicine|January 27, 2022
Repurposing of Medicines in the EU: Launch of a Pilot FrameworkCharlotte Asker-Hagelberg, Tomas Boran, Christelle Bouygues, et al.
Frontiers in Medicine|July 25, 2025
Multistakeholder scientific advice for medicinal products used in combination with a medical device or a companion diagnostic in the EU-summary of a Focus group discussionStiina Aarum, Claudia Popp, Alexa Hunter, et al.
Cancer Treatment Reviews|August 11, 2025
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancersSilvia Stacchiotti, Pan Pantziarka, Hugh Leonard, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|July 16, 2019
A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and WhyMwango Kashoki, Zahra Hanaizi, Stella Yordanova, et al.
Clinical Pharmacology and Therapeutics|May 3, 2023
Biomarker-Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European UnionCiska Verbaanderd, Ana Trullás Jimeno, Jörg Engelbergs, et al.
Frontiers in Medicine|January 27, 2022
Repurposing of Medicines in the EU: Launch of a Pilot FrameworkCharlotte Asker-Hagelberg, Tomas Boran, Christelle Bouygues, et al.
Frontiers in Medicine|July 25, 2025
Multistakeholder scientific advice for medicinal products used in combination with a medical device or a companion diagnostic in the EU-summary of a Focus group discussionStiina Aarum, Claudia Popp, Alexa Hunter, et al.
Cancer Treatment Reviews|August 11, 2025
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancersSilvia Stacchiotti, Pan Pantziarka, Hugh Leonard, et al.
Pageof 1